Two factor XI antibodies, amrecibart and cenvacibart, prolonged aPTT without affecting PT in plasma, nonhuman primates and first-in-human studies of healthy volunteers; both prevented thrombosis without increased bleeding in primates and were generally well tolerated.
RCT
Chalothorn et al. Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)